Murphy, Jack F.
Mayourian, Joshua
Stillitano, Francesca
Munawar, Sadek
Broughton, Kathleen M.
Agullo-Pascual, Esperanza
Sussman, Mark A.
Hajjar, Roger J.
Costa, Kevin D.
Turnbull, Irene C. http://orcid.org/0000-0001-9105-8926
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K01-HL133424, R01-HL132226, F30 HL134283)
American Heart Association (17SDG33700093)
Article History
Received: 5 July 2019
Revised: 25 October 2019
Accepted: 5 November 2019
First Online: 4 December 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: K.D.C. holds equity in NovoHeart Holdings; research conducted in this study could potentially affect the value of NovoHeart. M.A.S. is the Chief Science Officer and Founding member of CardioCreate, Inc., a regenerative medicine company. The other authors declare that they have no competing interests.